Emerson, a global technology and software provider, has partnered with Sartorius to natively integrate Sartorius’ Biostat STR Generation 3 family of bioreactors with Emerson’s DeltaV distributed control system (DCS). The Biostat STR Generation 3 for Emerson’s DeltaV, a variant of the Biostat STR Generation 3 family, is a pre-engineered solution designed to deliver intuitive connectivity for accelerating and simplifying the process of bringing therapies to market.
 
Biostat STR Generation 3 natively-integrated with a plant’s DeltaV DCS aims to help eliminate the complexity associated with automation of operations for one of the most frequently used components of biopharmaceutical manufacturing. The bioreactors are specifically designed and pre-engineered with DeltaV components from the ground up by Sartorius. The configuration toolkit developed by Emerson and Sartorius has a library of templates that provide standardized configuration. 
 
Using the library, teams can integrate bioreactors into their control system quickly and commercial manufacturing sites can expect to save up to 80% of their equipment integration time, helping them take advantage of the enhanced features and diagnostics inherent in the DeltaV DCS more quickly and easily. 
 
Built-in templates provide standardized configurations for the most common uses, allowing teams to use standard setups out of the box to bring operations online rapidly and safely and allow them to change those operations quickly to meet shifting market needs.
 
The configuration and integration of the Biostat STR Generation 3 bioreactors integrated with the DeltaV DCS helps life sciences manufacturers build a connected plant, a core strategy of reaching level 3 of the Biophorum Digital Plant Maturity Model. Plants will also gain the ability to scale more easily, as installation techniques can be quickly and intuitively replicated across multiple process areas or even multiple facilities.
 
“One of the biggest barriers to fast delivery of new treatments is the time it takes to connect new equipment to the plant’s control system,” said Nathan Pettus, president of Emerson’s process systems and solutions business. “Working closely with Sartorius to seamlessly incorporate our DeltaV technologies and software into Sartorius bioreactors, we jointly have made one of the most critical components of biopharmaceutical manufacturing ready to connect out of the box for faster speed-to-market.” 
 
“The biopharmaceutical industry requires modular and scalable bioprocess equipment to help quickly and easily manufacture the treatments patients around the world are waiting for,” said Mario Becker, head of bioreactor technologies at Sartorius. “By integrating Emerson software and technology into our new Biostat STR DeltaV variant, we help our customers rapidly bring their operations online while also maintaining flexibility, scalability, and the current Good Manufacturing Practice strategies that are critical to delivering high-quality treatments.”